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Letters to the Editor 
Dear Editor 
NK cells in non-neoplastic lung tissue. Initial results 
The importance of NK cells in the host response 
against tumours is known, but these cells have not 
been accurately studied in non-neoplastic lung tissue 
(1,2). The aim of this study is to evaluate the presence 
of NK cells in non-neoplastic lung tissue. 
Twelve lung biopsies of patients with non- 
neoplastic disease were analysed. No patients had 
received previous radiation and none of them had 
acute inflammatory disease. Historical analysis was 
done in paraffin-embedded sections. Immunohisto- 
chemical stains were performed for NK cells using 
the monoclonal antibody IOT-10 (CD 56). The 
number of NK cells was counted with a MICRON 
image analyzer. 
The total area measured for each biopsy was 
447590pm’. In this area, we deducted the alveolar 
air space, by digital technology. The mean area of 
the interstitial tissue studied was 293840pm’ 
(minimum=234413 and maximum=362108). 
In the biopsies analysed, the number of NK cells 
was between 2 and 13 (mean value = 1.97/100000 pm’; 
minimum=0.68 and maximum=3.59). 
We conclude there are few NK cells in non- 
neoplastic lung tissue free from inflammatory 
disease. 
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Dear Editor 
Turbuhaler or nebulizer therapy in severe COPD 
I read with interest the paper by Hansen et al. (1). 
They present evidence that high dose bronchodilator 
therapy given by dry powder inhaler can be as 
effective as nebulizer therapy. This fits well with their 
own previous comparisons of nebulized and dry 
powder therapy and the paper is in agreement with 
studies that have shown that high dose broncho- 
dilator therapy is equally effective whether given by 
nebulizer or by metered dose inhaler. 
The authors are correct in stating that dry powder 
therapy is more convenient for the patient than 
nebulizer therapy but, unfortunately, it is my experi- 
ence that most U.K. COPD patients with home 
nebulizers tend to use a combination of p-agonist and 
anti-cholinergic therapy. 
Unfortunately, the latter cannot be given by dry 
powder at present (at least in the U.K.). The benefits of 
convenience would therefore be lost for many patients. 
More importantly, the discussion contains a mis- 
leading statement that ‘the costs of dry powder treat- 
ment are considerably less than the cost of domiciliary 
nebulizer therapy.’ This statement is very inaccurate 
for U.K. prescribers. The present cost of terbutaline 
treatment is as follows: Bricanyl respirator solution 
5 mg qid costs f96.00 per annum. Bricanyl respules 
5Omg qid would cost E267.00 per annum. Bricanyl 
turbohaler 2.5 mg qid would cost E652.00 per annum. 
Although the nebulizer user would have an initial 
cost of approximately ~&100.00 to purchase a com- 
pressor and some small running costs for disposable 
items, the dry powder treatment is either twice as 
expensive or six times as expensive depending on 
which nebulizer product is used. 
A switch to dry powder treatment would not 
therefore be an economically attractive option for 
U.K. prescribers and I would be interested if the 
authors would give comparative costs for treatment 
in Denmark and in other countries where the dry 
powder preparation is available. 
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